Printer Friendly
The Free Library
23,375,127 articles and books


Pharmaceutical Expert Available to Comment On: Sharp Rise in Number of Clinical Drug Trials and Patients' Exposure to Experimental Drugs.

PALO ALTO, Calif.--(BW HealthWire)--Aug. 3, 1998--The trade association that represents the U.S. pharmaceutical and biotechnology industries recently reported that the average number of clinical trials per New Drug Application (NDA) has more than doubled -- from 30 to 68 -- from 1981-84 to 1994-95. During this same time period, the average number of patients participating in clinical evaluation of an experimental drug has risen from 1,321 to a staggering 4,237. These increases can be partially attributed to the growing complexity of new drug compounds and increasing regulatory guidelines.

In its 1998 Industry Report, the Pharmaceutical Research and Manufacturers of America (PhRMA) estimates that pharmaceutical companies will invest more than $20 billion in research and development this, a 10% increase from 1997. Currently, it costs about $500 million and 15 years to bring a new drug to market, with clinical trials accounting for approximately one-half of the time and one-third of the cost required. In an effort to streamline the number of clinical trials -- and reduce the number of patients exposed to experimental drugs during these trials, pharmaceutical and biotech companies are turning to the high-tech world of computer simulation for help.

Stuart Koretz, MD, PhD, vice president of medical affairs and business development, for Pharsight is available to comment on the R&D challenges pharmaceutical and biotechnology industries are facing. Dr. Koretz has more than 15 years of experience in drug development across a broad range of therapeutic areas. He was previously vice president, new products discovery, at ALZA Corporation, where he focused on utilizing advanced delivery systems to improve the performance of drugs.

Pharsight Corporation, located in the midst of Silicon Valley and Biotech Bay, provides drug companies with computer-assisted trial design (CATD) software to design better, and eventually fewer, clinical trials. Pharsight's Trial Designer technology allows researchers to assess proposed clinical studies and determine which will be the most effective and least costly trial. By designing more efficient trials, Pharsight's technology can reduce the number of clinical studies performed per NDA and lessen the number of patients' exposed to experimental drugs. Glaxo Wellcome and Parke Davis are currently using Pharsight's software.

To schedule an interview with Dr. Koretz, please contact Laura Koziol or Gavin Skillman at Schwartz Communications, Inc., at 415/512-0770.

 CONTACT: Schwartz Communications, Inc.
 Laura Koziol or Gavin Skillman, 415/512-0770


COPYRIGHT 1998 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1998, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Article
Geographic Code:1USA
Date:Aug 3, 1998
Words:388
Previous Article:Offshore Logistics, Inc. Announces Earnings for the Fiscal Quarter Ended June 30, 1998.
Next Article:Franklin Templeton Introduces Franklin Bond Fund.
Topics:



Related Articles
Proposal seeks wider access to AIDS drugs.
The what's and why's of clinical trials.
Rising concerns about placebos.
FDA Gives Salvage Therapy Testing a Push Forward.
AMGEN, HYSEQ IN DRUG DEAL ALFIMEPRASE DESIGNED TO TREAT LEG BLOOD CLOTS.
UCLA CANCER DRUG RESEARCH RESULTS ENCOURAGING.
SCICLONE'S SCV-07 THERAPY YIELDS GOOD RESULTS FOR TB.
The salvage therapy II think tank.
Breaking into clinical research.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters